Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

por Jackson, Kimberley, Chua, Laiyi, Velez de Mendizabal, Nieves, Pitou, Celine, Rodriguez Capriles, Claudia, Paller, Amy S., Lansang, Perla, Seyger, Marieke M. B., Papp, Kim
Publicado 2021

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediat...

por Hebert, Adelaide A., Bobonich, Margaret A., Rodriguez Capriles, Claudia, Gallo, Gaia, Li, Lingnan, Somani, Najwa, Ridenour, Terri, Wang, Yan, Edson‐Heredia, Emily, Becker, Emily M.
Publicado 2021

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

por Paller, Amy S., Seyger, Marieke M. B., Magariños, Gabriel A., Pinter, Andreas, Cather, Jennifer C., Rodriguez-Capriles, Claudia, Zhu, Danting, Somani, Najwa, Garrelts, Alyssa, Papp, Kim A.
Publicado 2022

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

por Paller, Amy S., Flohr, Carsten, Eichenfield, Lawrence F., Irvine, Alan D., Weisman, Jamie, Soung, Jennifer, Pinto Correia, Ana, Natalie, Chitra R., Rodriguez Capriles, Claudia, Pierce, Evangeline, Reifeis, Sarah, Gontijo Lima, Renata, Armengol Tubau, Clara, Laquer, Vivian, Weidinger, Stephan
Publicado 2023